- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01630070
Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries (PES-BTK-70)
March 6, 2015 updated by: Flanders Medical Research Program
A Prospective, Multi-center, Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent in the Treatment of Atherosclerotic Tibial-peroneal Arteries
The objective of this clinical study is to evaluate the immediate and long-term (up to 12 month) safety and effectiveness of a Nitinol Self-Expanding Paclitaxel-Eluting stent for the treatment of patients with critical limb ischemia (i.e.
rest pain or non-healing foot ulcers) due to the presence of arterial lesions in the below-the-knee arteries of maximally 50mm long.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Antwerp
-
Bonheiden, Antwerp, Belgium, 2820
- Imelda Hospital
-
Edegem, Antwerp, Belgium, 2650
- UZA
-
Tienen, Antwerp, Belgium, 3300
- RZ Heilig-Hartziekenhuis
-
-
East-Flanders
-
Aalst, East-Flanders, Belgium, 9300
- OLV Ziekenhuis
-
Dendermonde, East-Flanders, Belgium, 9200
- AZ Sint-Blasius
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient presenting with rest pain or minor tissue loss (Rutherford Clinical Category 4 or 5)
- Patient is willing to comply with specified follow-up evaluations at the specified times
- Patient is >18 years old
- Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- Patient has a projected life-expectancy of at least 12 months
- Patient is eligible for treatment with a Self-Expanding Paclitaxel-Eluting stent
- Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
- Evidence at screening of ≥50% de novo lesion (or restenosis after previous PTA) in the infrapopliteal arteries, confirmed by angiography
- Reference vessel diameter visually estimated to be ≥3.0mm and ≤4.5mm
- Identifiable distal target vessel which upon completion of the intervention, is anticipated to provide reconstitution of blood flow to the foot.
- Guidewire successfully traversed lesion
- Length of target lesion is <50mm
Exclusion Criteria:
- Untreated flow-limiting inflow lesions
- Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
- Has had a previous peripheral bypass affecting the target limb
- Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
- Non-atherosclerothic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- Patient has a contra-indication or known untreated allergy to anti-platelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used
- Patient has hypersensitivity to contrast or device material that cannot be adequately pretreated
- Patient has known uncontrollable hypercoagulable condition, or refuses blood transfusion
- Life expectancy of less than 12 months
- Patient is currently participating in an investigational drug or another device study that may clinically interfere with the study endpoints
- Patient has other co-morbid condition(s) that in the judgment of the physician precludes safe percutaneous intervention
- Has end-stage renal disease defined as undergoing hemodialysis for kidney failure
- Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
- Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT)type II
- Treatment of ipsilateral non-study inflow lesions with other materials than regular guidewires, regular PTA balloons, bare metal stents and/or paclitaxel-coated stents
- Additional treatments of the study lesion requiring materials/procedures other than standard guidewires, regular PTA balloons and/or a Self-Expanding Paclitaxel-Eluting stent (e.g. thrombectomy, re-entry catheters, CTO-wires, cutting balloon, cryoballoon, etc)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Self-expandable drug eluting stent
Self-Expanding Paclitaxel-Eluting stent
|
Self-Expanding Paclitaxel-Eluting stent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary patency
Time Frame: 6 months
|
Primary patency rate at 6 months, defined by duplex ultrasound measurement of peak systolic velocity ratio ≤2.0 at the target lesion(s) with no clinically-driven reintervention within the treated segment, verified by Core Lab
|
6 months
|
Primary patency
Time Frame: 12 months
|
Primary patency at 12 months, defined as absence of restenosis (≥50% stenosis) or occlusion within the originally treated lesion based on angiography, verified by Core Lab
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success
Time Frame: procedure (day 0)
|
Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% by visual assessment
|
procedure (day 0)
|
Procedural success
Time Frame: Procedure (day 0)
|
Procedural success, defined as the ability to achieve <30% final residual stenosis of the target lesion by visual estimation (angio) and the absence of any in-hospital Major Adverse Events (MAE, defined as clinically-driven target vessel revascularization, major unplanned amputation of the treated limb, and all-cause mortality)
|
Procedure (day 0)
|
MAE (Major Adverse Event)
Time Frame: 1, 6 and 12 months
|
MAE at 1, 6 and 12 months Major Adverse Events (MAE) include (but are not limited to)
|
1, 6 and 12 months
|
SAE (Serious Adverse Event)
Time Frame: discharge, 1, 6 and 12 months
|
Other SAEs at discharge, 1, 6 and 12 months A Serious Adverse Event (SAE) is defined as an Adverse Event which:
|
discharge, 1, 6 and 12 months
|
Improvement of Rutherford classification
Time Frame: 12 months
|
Improvement in Rutherford Clinical Category at 12 months, defined as an improvement in clinical status indicated by a decrease of one or more in Rutherford Clinical Category at 12 months compared to baseline, that is attributable to the treated limb (in cases of bilateral disease)
|
12 months
|
Improvement in Ankle-Brachial Index
Time Frame: 12 months
|
Improvement in Ankle-Brachial Index at 12 months, defined as an increase in the ankle-brachial index (ABI) at 1 year compared to baseline in subjects with compressible arteries and baseline ABI<0.9
|
12 months
|
Primary Patency
Time Frame: 1 and 12 months
|
Primary patency rate at 1 and 12 months, defined by duplex ultrasound measurement of peak systolic velocity ratio ≤2.0 at the target lesion(s) with no clinically-driven reintervention within the treated segment
|
1 and 12 months
|
Secondary patency
Time Frame: 1, 6 and 12 months
|
Secondary patency rate at 1, 6 and 12 months, defined by duplex ultrasound peak systolic velocity ratio ≤2.0 maintained by repeat percutaneous intervention
|
1, 6 and 12 months
|
Limb salvage rate
Time Frame: Procedure, 1, 6 and 12 months
|
Limb salvage rate, defined as 1 minus major amputation rate (major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot
|
Procedure, 1, 6 and 12 months
|
Target Lesion Revascularisation
Time Frame: Procedure (day 0), 1, 6 and 12 months
|
Target lesion revascularization (TLR), defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge.
|
Procedure (day 0), 1, 6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Marc Bosiers, MD, AZ Sint-Blasius
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (ACTUAL)
October 1, 2013
Study Completion (ACTUAL)
October 1, 2014
Study Registration Dates
First Submitted
June 18, 2012
First Submitted That Met QC Criteria
June 26, 2012
First Posted (ESTIMATE)
June 28, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
March 9, 2015
Last Update Submitted That Met QC Criteria
March 6, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- FMRP-110629
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Self-expandable drug eluting stent
-
Yonsei UniversityUnknownColorectal CancerKorea, Republic of
-
Seoul National University HospitalRecruitingMalignant Biliary ObstructionKorea, Republic of
-
Southeast University, ChinaCompletedPancreatic Cancer | Gallbladder Cancer | Cholangiocellular Carcinoma | Metastatic CarcinomaChina
-
Korea University Guro HospitalCompletedAtherosclerosis | Peripheral Artery DiseaseKorea, Republic of
-
Khon Kaen UniversityCompletedHilar CholangiocarcinomaThailand
-
Erasmus Medical CenterNot yet recruiting
-
Allium, Ltd.WithdrawnMalignant Obstruction of the Common Bile DuctIsrael
-
Johns Hopkins UniversityBoston Scientific CorporationRecruitingGastric Outlet ObstructionUnited States, India, France, Canada, Ecuador, Spain
-
StentysTerminatedAcute Myocardial InfarctionNetherlands, United States
-
Khon Kaen UniversityUnknownUnresectable Hilar CholangiocarcinomaThailand